4F-MBZP

The following information was compiled in June 2025 and is subject to change as new research is conducted and as new information becomes available:

Description: 4F-MBZP is a novel stimulant classified as a piperazine and is structurally similar to other derivatives of benzylpiperazine (BZP). Fluorinated MBZP exists in three isomeric forms (2F-, 3F-, and 4F-); however, only 4F-MBZP has been identified to date. 4F-MBZP was first identified from the Australian drug checking service CanTEST in June 2023.¹ 4F-MBZP was identified by our laboratory in January 2025 and confirmed after acquiring standard reference material.

Sample Source: StreetCheck (Massachusetts, Northeast)

Sample Appearance: Green tablet

Pharmacology: The activity and potency of 4F-MBZP have not been explicitly studied; however, due to structural similarity to other benzylpiperazines, it is assumed that 4F-MBZP stimulates the release and inhibits the reuptake of neurotransmitters to cause dopaminergic and serotonergic effects.^2,3

Toxicology: 4F-MBZP has not been detected in toxicology cases to date at the CFSRE.

Drug Materials: 4F-MBZP has been detected in two drug materials to date at the CFSRE.

Demographics / Geographics: Drug materials originated from Massachusetts and Pennsylvania, and 4F-MBZP was found alongside designer benzodiazepines (e.g., bromazolam) and novel stimulants.

Legal Status: 4F-MBZP is not currently scheduled in the United States.

Class:

Stimulant

Appearance:

Green tablet

Formula:

C12H17FN2

MW:

208.3

[M+]:

208

[M+H]+:

209.1449

IUPAC:

1-[(4-fluorophenyl)methyl]-4-methyl-piperazine

Report Date:

June 18, 2025